Pediatric BLS: Difference between revisions
Neepa Shah (talk | contribs) (Created page with "__NOTOC__ {{Pediatric BLS}} {{CMG}}; {{AE}}{{N.S}} ==Overview== Waldenström macroglobulinemia was first discovered by Jan G. Waldenström, a Swedish physician in 19...") |
Neepa Shah (talk | contribs) No edit summary |
||
| Line 2: | Line 2: | ||
{{Pediatric BLS}} | {{Pediatric BLS}} | ||
{{CMG}}; {{AE}}{{ | {{CMG}}; {{AE}}{{Neepa Shah}} | ||
== | ==Introduction== | ||
[[Waldenström macroglobulinemia]] was first discovered by Jan G. Waldenström, a Swedish [[physician]] in 1944. [[Bing-Neel syndrome]], a late and [[rare]] [[complication]] of [[lymphoplasmacytic lymphoma]], was first discovered in 1936 by Jens Bing and Axel Valdemar Neel. First report on [[familial]] [[aggregation]] of [[Waldenstrom macroglobulinemia]] was published in 1962. In 1944, Revised European-American [[classification]] of [[lymphoid]] [[neoplasms]] (REAL) and [[World Health Organization|WHO]] in 2001, placed [[Waldenstrom macroglobulinemia]] in the [[Category utility|category]] of [[lymphoplasmacytic lymphoma]]. A [[diagnostic criteria]] for [[Waldenstrom macroglobulinemia]] was proposed by a [[Consensus (medical)|consensus]] [[Group (sociology)|group]] at the [[Second]] International Workshop in Athens, Greece in 2002. A report published in 2013 showed that a [[patient]] of [[Bing–Neel syndrome|Bing-Neel syndrome]] who discontinued the [[Treatments|treatment]] in 2009 remained [[asymptomatic]]. | [[Waldenström macroglobulinemia]] was first discovered by Jan G. Waldenström, a Swedish [[physician]] in 1944. [[Bing-Neel syndrome]], a late and [[rare]] [[complication]] of [[lymphoplasmacytic lymphoma]], was first discovered in 1936 by Jens Bing and Axel Valdemar Neel. First report on [[familial]] [[aggregation]] of [[Waldenstrom macroglobulinemia]] was published in 1962. In 1944, Revised European-American [[classification]] of [[lymphoid]] [[neoplasms]] (REAL) and [[World Health Organization|WHO]] in 2001, placed [[Waldenstrom macroglobulinemia]] in the [[Category utility|category]] of [[lymphoplasmacytic lymphoma]]. A [[diagnostic criteria]] for [[Waldenstrom macroglobulinemia]] was proposed by a [[Consensus (medical)|consensus]] [[Group (sociology)|group]] at the [[Second]] International Workshop in Athens, Greece in 2002. A report published in 2013 showed that a [[patient]] of [[Bing–Neel syndrome|Bing-Neel syndrome]] who discontinued the [[Treatments|treatment]] in 2009 remained [[asymptomatic]]. | ||
Revision as of 17:20, 8 June 2020
|
Pediatric BLS Microchapters |
|
Approach to a Suspected Patient of Cardiac or Respiratory Arrest |
|---|
|
Basic Life Support Guidelines (Revised American Heart Association 2010 Guidelines) |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Neepa Shah, M.B.B.S.[2]
Introduction
Waldenström macroglobulinemia was first discovered by Jan G. Waldenström, a Swedish physician in 1944. Bing-Neel syndrome, a late and rare complication of lymphoplasmacytic lymphoma, was first discovered in 1936 by Jens Bing and Axel Valdemar Neel. First report on familial aggregation of Waldenstrom macroglobulinemia was published in 1962. In 1944, Revised European-American classification of lymphoid neoplasms (REAL) and WHO in 2001, placed Waldenstrom macroglobulinemia in the category of lymphoplasmacytic lymphoma. A diagnostic criteria for Waldenstrom macroglobulinemia was proposed by a consensus group at the Second International Workshop in Athens, Greece in 2002. A report published in 2013 showed that a patient of Bing-Neel syndrome who discontinued the treatment in 2009 remained asymptomatic.